key: cord-0997318-pfxhoiiy
authors: Chowdhury, Kona; Haque, Mainul; Nusrat, Nadia; Adnan, Nihad; Islam, Salequl; Lutfor, Afzalunnessa Binte; Begum, Dilara; Rabbany, Arif; Karim, Enamul; Malek, Abdul; Jahan, Nasim; Akter, Jesmine; Ashraf, Sumala; Hasan, Mohammad Nazmul; Hassan, Mahmuda; Akhter, Najnin; Mazumder, Monika; Sihan, Nazmus; Naher, Nurun; Akter, Shaheen; Zaman, Sifat Uz; Chowdhury, Tanjina; Nesa, Jebun; Biswas, Susmita; Islam, Mohammod Didarul; Hossain, Al Mamun; Rahman, Habibur; Biswas, Palash Kumar; Shaheen, Mohammed; Chowdhury, Farah; Kumar, Santosh; Kurdi, Amanj; Mustafa, Zia Ul; Schellack, Natalie; Gowere, Marshall; Meyer, Johanna C.; Opanga, Sylvia; Godman, Brian
title: Management of Children Admitted to Hospitals across Bangladesh with Suspected or Confirmed COVID-19 and the Implications for the Future: A Nationwide Cross-Sectional Study
date: 2022-01-14
journal: Antibiotics (Basel)
DOI: 10.3390/antibiotics11010105
sha: dc19b07c13a4d5fe4c0ef0e1cfc201d1bad4a586
doc_id: 997318
cord_uid: pfxhoiiy

There is an increasing focus on researching children admitted to hospital with new variants of COVID-19, combined with concerns with hyperinflammatory syndromes and the overuse of antimicrobials. Paediatric guidelines have been produced in Bangladesh to improve their care. Consequently, the objective is to document the management of children with COVID-19 among 24 hospitals in Bangladesh. Key outcome measures included the percentage prescribed different antimicrobials, adherence to paediatric guidelines and mortality rates using purposely developed report forms. The majority of 146 admitted children were aged 5 years or under (62.3%) and were boys (58.9%). Reasons for admission included fever, respiratory distress and coughing; 86.3% were prescribed antibiotics, typically parenterally, on the WHO ‘Watch’ list, and empirically (98.4%). There were no differences in antibiotic use whether hospitals followed paediatric guidance or not. There was no prescribing of antimalarials and limited prescribing of antivirals (5.5% of children) and antiparasitic medicines (0.7%). The majority of children (92.5%) made a full recovery. It was encouraging to see the low hospitalisation rates and limited use of antimalarials, antivirals and antiparasitic medicines. However, the high empiric use of antibiotics, alongside limited switching to oral formulations, is a concern that can be addressed by instigating the appropriate programmes.

The principal focus on children in low-and middle-income countries (LMICs) during the COVID-19 pandemic has been to address key issues, including the poor uptake of vaccinations and the envisaged impact as well as behavioural issues as a consequence of lockdowns and social distancing measures [1] [2] [3] [4] [5] [6] . This resulted in Bangladesh organising immunisation outreach services for children and increasing the number of home visits to address concerns [3, 7] . This is because children have a lower risk of infection with Antibiotics 2022, 11, 105 3 of 18 COVID-19 than adults, with typically milder clinical manifestations [8] [9] [10] [11] [12] [13] [14] and an appreciable number are asymptomatic [11, 15] . Cough, fever, diarrhoea, nausea and respiratory infections are generally the most frequent clinical characteristics of children with COVID-19, with boys typically more prone than girls [8, [11] [12] [13] 15, 16] . Overall, it is estimated that approximately 6% to 10% of infected children experience severe disease, lower than rates seen in adults [11, 12] . Consequently, the focus among children during the current pandemic has been on other infectious diseases and their prevention.

However, the focus on children is changing with new variants and their potential implications. In addition, whilst a lower percentage of children with severe symptoms are admitted to intensive care units (ICUs) in LMICs, deaths among the hospitalised children are higher [12] .

There are also increasing concerns with the inappropriate use of antimicrobials across LMICs. Patients with COVID-19 in hospitals are typically administered antibiotics despite only a limited number having concomitant bacterial or fungal infections [17] [18] [19] [20] [21] [22] . This includes hospitals in Bangladesh [23, 24] . However, high inappropriate prescribing will increase antimicrobial resistance (AMR) rates, increasing morbidity, mortality and costs [25] [26] [27] [28] [29] [30] [31] [32] , with high rates of AMR already a concern in Bangladesh [ [33] [34] [35] [36] . Children with COVID-19 can also develop Kawasaki Disease (KD)-like symptoms/hyperinflammatory syndromes [8, [37] [38] [39] as well as experience leucopoenia with marked lymphopenia, hyponatremia, hypoalbuminemia, gastrointestinal and respiratory changes [37] , potentially increasing ICU admissions.

There have also been concerns generally with the level of misinformation surrounding the management of COVID-19. This includes issues with hydroxychloroquine, lopinavir/ ritonavir, remdesivir and ivermectin, with robust studies suggesting limited clinical benefit, although systematic reviews have suggested remdesivir can accelerate clinical improvement [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . This is a concern as misinformation can increase morbidity, mortality and costs [50] [51] [52] [53] . Concerns with misinformation have resulted in groups, including the World Health Organization (WHO) and the British Medical Journal (BMJ), providing evidence-based guidance [54] [55] [56] [57] [58] . International guidelines have also been developed to improve the management of children with COVID-19 in paediatric intensive care unit (PICU) countries [59] . The Ministry of Health and Family Welfare in Bangladesh also made national guidelines available from May 2020 onwards [60] . Similarly, the Bangladesh Paediatric Association has published its guidelines as this patient population is inherently a vulnerable one (Table 1 ) [61] . Table 1 . Key recommendations for managing adults and children with COVID-19 in hospitals in Bangladesh (adapted from [60, 61] Consequently, we believe it is important to document the current management of children admitted to hospitals in Bangladesh with suspected or confirmed COVID-19, especially given concerns with antimicrobial use. In view of this, the objective of this study is to document current prevalence rates, treatments and outcomes of children with COVID-19, admitted to hospitals in Bangladesh in recent months. The findings can be used to suggest future quality improvement programmes in Bangladesh and other countries, if pertinent.

We will first document the characteristics of patients admitted to hospitals across Bangladesh before documenting prescribed treatments and patient outcomes. One hundred and forty-six children were admitted with COVID-19 to the 24 hospitals taking part in this study, giving an overall prevalence of 3.7% (n = 3902, range = 0.55% to 29.5%) during the study period. COVID-19 was confirmed in the majority of admitted children by PCR tests (n = 111, 76%). The majority of admitted children were boys (n = 86, 58.9%) and were aged between 0 and 5 years (n = 91, 62.3%) ( Table 2 ).

The consolidated principal reasons for hospital admission are documented in Table 3 based on pre-determined choices (Methodology Section 4.2), with only a limited number of children (n = 20, 13.7% including one referral) transferred to the PICU, typically with low oxygen saturation (Table 3, Figure 1 ). Children were typically admitted with more than one symptom, with Table 3 documenting the consolidated principal reasons for admission among participating hospitals. Potential reasons for admission to the PICU were also pre-determined and are documented in the Methodology Section 4.2. There were only a limited number of comorbidities among admitted children with COVID-19. These included bronchial asthma, dilated cardiomyopathy, congenital heart disease, dengue, nephrotic syndrome, malnutrition, pneumonia, sepsis and urinary tract infections. Table 4 contains the consolidated list of antibiotics (class or specific) prescribed for children with suspected or confirmed COVID-19 among the participating hospitals. As seen, there was a considerable prescribing of antibiotics, with 86.3% (126/146) of children prescribed them, with almost all antibiotics administered empirically (98.4%-124/126). In general, antibiotics were prescribed from the WHO Watch list as opposed to the Reserve list. In addition, antibiotics were typically administered parenterally with generally limited prescribing of oral antibiotics, including switching, for between 3 and 14 days. Children were generally assessed after 2 to 3 days (Table 4) . There was no prescribing of hydroxychloroquine for any child admitted with COVID-19 in the surveyed hospitals and very limited prescribing of either antivirals, including remdesivir, or antiparasitic medicines, including ivermectin (Table 4 ). Steroids were prescribed to children in 13 of the surveyed hospitals (n = 13, 54.2%), with immune boosters, including vitamins C and D, prescribed to children in 14 of the participating hospitals (n = 14, 58.3% of hospitals).

There were lower rates of prescribing of antibiotics among those hospitals where the clinicians stated that they had followed the Bangladesh Paediatric Association guidelines (Tables 1 and 5 ). However, there was no significant statistical association (p = 0.127) between the administration of antibiotics and the clinicians in the participating hospitals who had stated they had complied with the Paediatric Association guidelines when prescribing antibiotics to children with suspected or confirmed COVID-19 and those who had not (Table 5 ). 

To the best of our knowledge, this is the first comprehensive study conducted among a range of both private and public hospitals across Bangladesh concerning the management of children hospitalised with suspected or confirmed COVID-19. Our findings build on the earlier study of Hussain et al. (2020), who found a higher mortality rate (13.3%) among children during the early stages of the pandemic [3] , and the recent pilot studies conducted among children in Bangladesh and India [62, 63] . The reduced mortality among children hospitalised with COVID-19 in our study (1.4%) compared with the study conducted by Hussain et al. (2020) may reflect improved clinical management as more knowledge is gained regarding the aetiology of COVID-19, especially with greater recognition of Kawasaki disease (KD)-like symptoms/hyperinflammatory syndromes among these children [8, [37] [38] [39] . In addition, greater knowledge of treatment approaches has resulted in the development of updated guidelines (Table 1 ) as well as updated advice from groups such the WHO and the BMJ [54, 58] . However, further research is needed on this topic before we can say anything with certainty. Having said this, only a low number of children were admitted to these general hospitals in Bangladesh with COVID-19 (Table 2) , similar to the findings of other recent publications, including the recent pilot study in India [11, 13, 15, 63] .

Fever, cough and respiratory diseases were, again, the most frequent clinical characteristics of children admitted to the surveyed hospitals with COVID-19 (Table 3 , Figure 1) , with admission to hospital with suspected or confirmed COVID-19 also more common among boys (58.9%), similar to other studies [8, [11] [12] [13] 15, 16, 63] .

Encouragingly there was limited prescribing of antiviral, antiparasitic and antimalarial medicines among the children with COVID-19 admitted to the surveyed hospitals (Table 4 ). This is in line with recommendations in the Bangladesh Paediatric guidelines (Table 1) , with similar guidance in other countries [61, 64, 65] . This is important given concerns with the lack of effectiveness of these medicines in treating patients with COVID-19, despite the initial hype [40, 41, 43, 44] . Encouragingly, the prescribing of immunomodulators such as vitamins and zinc also appeared to be in line with the paediatric guidelines (Table 1) . However, we are beginning to see immunomodulators being discouraged in some LMICs [65] .

However, there were concerns with the high empiric use of antibiotics among the children in the surveyed hospitals (Table 3) , which is similar to their high use among adults admitted to hospitals with COVID-19 in Bangladesh [23, 24] . These rates (86.3%) are higher than a recent pilot study undertaken in India, with rates of 69.4% [63] . This is despite, as mentioned, only a limited number of patients with COVID-19 across ages having concomitant bacterial or fungal infections [17] [18] [19] [20] [21] [22] 31, 66] . In addition, the Paediatric Association guidelines advocate only the prudent use of antibiotics due to concerns with potential over-use (Table 1) . However, the rates of antibiotic prescribing appear to be less among children where the clinicians have stated they followed paediatric guidelines (Table 5) ; however, this was not statistically significant. In any event, these high rates need to be addressed, going forward, to reduce future AMR.

Potential ways forward to improve the rational use of antibiotics among these children include instigating antimicrobial stewardship programmes (ASPs), combined with an additional COVID-19 module, and other educational activities; these currently do not exist. Such activities have been successful across LMICs to improve the rational use of antibiotics in a number of situations [28, 29, 32, 36, [67] [68] [69] [70] [71] [72] .

Future activities should also include encouraging antibiotic prescribing according to local antibiograms where initial prescribing is typically empiric, combined with instigating ASPs [35, [73] [74] [75] . These combined activities should help reduce the extent of prescribing 'Watch' antibiotics in favour of the increased prescribing of 'Access' antibiotics, where pertinent (Tables 2 and 4 ) [76, 77] . ASPs could also potentially encourage earlier switching from parental to oral antibiotics where it is pertinent and practical to hasten earlier discharge and conserve resources [78] [79] [80] . This is important with the current practice of limited switching to oral antibiotics among the surveyed hospitals. We will be following up on these identified issues in future studies to improve antibiotic prescribing in Bangladesh, given continual concerns with high rates of AMR [33] [34] [35] 81] .

The seemingly low number of children admitted to these general hospitals in Bangladesh versus other conditions is important when considering future priorities with limited resources. This includes reviewing the clinical conditions of the other admitted children during this period without COVID-19 and whether resources should be focused on these children instead. In addition, there are key areas such as vaccinations to prevent future infections among children [28] . We are aware that in Bangladesh and other LMICs, vaccination rates have been appreciably compromised by lockdowns and other measures [1] [2] [3] [4] [5] . Whilst this was not a focus for this study, we are aware that the direct and indirect impact of COVID-19 on children has been underestimated. Children in LMICs are more likely to suffer from other comorbidities such as other respiratory tract infections, including pneumonia as well as malnutrition and HIV, which may complicate a COVID 19 diagnosis [82] . Consequently, we will also be following up on these issues as well in future research projects to provide additional guidance to all key stakeholder groups in Bangladesh and other countries.

We are aware of several limitations with this study. These included the fact that this was only a retrospective review of medical records without the ability to check with physicians regarding the rationale for any prescribing, especially of antibiotics. We were also limited by the extent of information that could be collected from the surveyed hospitals, and all cases of COVID-19 could not be confirmed by rt-PCR. We also could not analyse any differences between private and public hospitals as admission and other key criteria were not standardised. In addition, we extended the study period in each hospital in order to collect more data on the management of children with COVID-19. Consequently, our prevalence rates of admitted children could be overestimated. However, despite these limitations, we believe our findings are robust, given the number of participating hospitals, providing direction for future quality improvement programmes and other activities.

The study was undertaken among a range of hospitals (n = 24) across Bangladesh, admitting children with suspected or confirmed COVID-19. Both private and public hospitals were included to ensure full representation, similar to point prevalence surveys conducted in other healthcare systems with a mixture of hospital types [83] [84] [85] . Initially, children in Bangladesh with COVID-19 were referred to public hospitals, mainly medical college hospitals. However, this changed, with private hospitals subsequently able to treat children admitted with COVID-19.

Private and public hospitals were not analysed separately due to anticipated different admission criteria, making comparisons problematic and difficult to justify. In addition, the aims of the study were to gain insights into current prevalence rates among children admitted with suspected COVID-19 to hospitals in Bangladesh, as well as insights into current management practices, rather than to assess differences in treatments and outcomes between different hospital types. This included the current prescribing of antimicrobials among hospitals in Bangladesh. The hospitals were purposely selected based on their ability to provide pertinent data as well as maximum variation in terms of their geography, location and size ( Table 2) .

This point prevalence survey was conducted based on standardised methodologies, with the data forms adapted to meet the specific requirements of the study and setting [62, [83] [84] [85] [86] [87] [88] (Supplementary Material File S1). Data were gathered from the medical records of children admitted to hospital with suspected or confirmed COVID-19 between July and November 2021. This included children subsequently admitted to PICUs, if such facilities existed in the hospital. Care in public hospitals in Bangladesh for these patients is typically provided without the need for co-payments. However, there are charges for patients admitted to private hospitals.

A paper-based data collection tool was used by the investigators to collect the necessary information at the patient level. The specific forms were adapted from previous point prevalence surveys conducted in LMICs involving a number of co-authors [83, [85] [86] [87] [88] [89] [90] [91] [92] . This was combined with a synthesis of current guidelines for managing children with COVID-19 in Bangladesh (Table 1) , a synthesis of the current literature [3, 11, 12, 20, 93] and a cognisance of the study aims and objectives. The data collection forms were pre-tested to ensure they would meet the study objectives. A pilot study was undertaken among a limited number of hospitals in Bangladesh [62] prior to full roll-out, with a similar pilot study undertaken in India [63] . The same forms were subsequently used in this multicentre study in Bangladesh as they were able to provide the relevant information to meet the aims and objectives of the study (Supplementary Material File S1).

There were no exclusion criteria. All children admitted on the day of data collection and during the previous nine days were included to give a combined total over a tenday period.

The key data sets collected and the rationale for their inclusion in the data collection forms, where pertinent, are included in Table 6 . The information was collected by the principal investigator in each hospital, with initial data collection taking place on one specific day, similar to other PPS studies. The medical records of patients admitted in the previous ten days were also viewed. Ten days were chosen for this study by the principal investigators because of the anticipated low numbers of children with COVID-19 actually admitted to general hospitals in Bangladesh on any specific day, with children with COVID-19 generally asymptomatic or with milder clinical manifestations versus adults [8, [10] [11] [12] [13] . Alongside this, there were anticipated low numbers of children with COVID-19 in the participating hospitals compared with other conditions of admitted children. In addition, as mentioned, the principal objective of the study was to gain knowledge of current management practices, including any concerns with antimicrobial use, rather than a robust assessment of prevalence rates. Children were also followed up, if necessary, to determine the average number of days they were prescribed antibiotics and when re-assessed. Table 6 . Key data sets collected and their rationale.

Number of paediatric patients being treated in the hospital during the ten-day period and the number with COVID-19

To gain insight into current prevalence rates among children admitted to hospitals in Bangladesh compared with other conditions

Whether COVID-19 was suspected or confirmed-confirmed with PCR tests To gain additional insight into current COVID-diagnostic practices

The ages of admitted children

Patients' ages were broken down into 3 bands: 0-5 years; 6-10 years; 11-18 years for comparative purposes based on the pilot study in both Bangladesh and India [62, 63] Principal reason for admission to hospital with actual/suspected COVID-19

• Potentially up to 3 principal reasons for admission could be recorded among participating hospitals • These were taken from a drop-down menu in the Microsoft Excel ® spreadsheets and consisted of (i) breathing difficulties/respiratory distress; (ii) prolonged fever; (iii) cough; (iv) diarrhoea; and (v) feeding difficulty/vomiting • These reasons were taken from the current literature, combined with input from paediatricians in Bangladesh, and tested in the pilot study [8, 9, [11] [12] [13] 62] • Consolidating the reasons would assist with analysis and comparisons with published studies Comorbidities Based on evidence amongst adults that certain comorbidities do have an impact on morbidity and mortality associated with COVID-19 [94, 95] Number of children admitted to PICU and the rationale

The potential reasons for admittance taken from the literature and input from paediatricians in Bangladesh included: (i) severe respiratory distress/low O 2 saturation; (ii) shock; (iii) coagulation disorders/thromboembolic manifestations; and (iv) extensive lung involvement in high-resolution CT scans (HRCTs) [9, 13, 62] • These potential reasons were standardised in the data collection forms for ease of recording and analysis and tested in the pilot study

Number of children prescribed antibiotics and the antibiotics prescribed (by ATC Level 4 Grouping or individual antibiotics), and whether empiric or following CST findings • This was assessed given concerns with potential over-prescribing coupled with guidance from the Bangladesh Paediatric Association, advocating prudence [61] • Antibiotic prescribing also assessed against the WHO Access, Watch, or Reserve (AwaRe) list, given the increasing importance of this list to guide future antimicrobial policies and practices [76, 86, 88, 96, 97] •

The list of antibiotics prescribed for admitted children in specific hospitals was provided in a menu in the Case Report Forms (Supplementary Material File S1) and consolidated for tabulation and analysis

Route of administration, whether the rationale for antibiotic prescribing was re-assessed, and, if so, after how many days, and total length of antibiotic prescriptions

• Given prior awareness that antibiotics administered to children admitted to hospital are usually administered by IV • To determine whether:

There was any scaling down to oral antibiotics, as this can shorten hospital length of stay [91, 98, 99] . If so, the extent There was any documented rationale for the antibiotics prescribed when re-assessed, especially with high empiric use, to help guide future quality improvement programmes among hospitals in Bangladesh Table 6 . Cont.

The extent of prescribing of antivirals, e.g., remdesivir, antimalarials, e.g., hydroxychloroquine, and antiparasitic medicines, e.g., ivermectin

• Assessed, given concerns with their effectiveness and safety as more robust data became available, and should be reserved if administered (antivirals) according to the Bangladesh Paediatric Guidelines [40, 43, 44, 46, 48, 61] Data were collated by the principal investigator in each participating hospital and subsequently entered into Microsoft Excel ® spreadsheets for analysis. As mentioned (Table 6) , these contained drop-down menus with options for specific questions. The aggregated data for each hospital was subsequently transferred to the principal investigator collating the findings (BG) for analysis, with the ability to re-check and re-validate data when the need arose with the co-authors from the pertinent hospitals.

Descriptive statistics were typically used to summarise and collate the data using proportions (%) as appropriate, given the likely differences in admittance criteria between hospitals. However, the chi-square statistical test was used to assess whether there were significant differences in antibiotic prescribing between those hospitals that stipulated they followed current guidelines versus the remainder, with a p-value < 0.05 seen as significant (Table 5 ).

Patient anonymity was maintained throughout the study by the principal investigator in each hospital. Only aggregated anonymised data for each hospital was forwarded to the principal investigator collating the findings (BG) for analysis. Additionally, in the final analysis, hospitals were assigned a study identification number rather than each hospital being specifically identified (Hospitals 1 to 24) .

Parents or guardians were not approached for consent since this was a retrospective study based on data collated from patients' medical records, with no direct contact with children, their parents, or guardians. This is in line with previous point prevalence surveys undertaken by the co-authors [84, 86, [88] [89] [90] 92, 112] .

The principal investigators orchestrated ethical approval for the hospitals and others involved in the study. The reference numbers are ibh/mirpur/2020/01; GSVMC/2021/346; BBEC, JU/M 2021/COVID-19/7 and AWMC/IRB-21 July 2021/028.

The low rates for the hospitalisation of children with COVID-19 among the surveyed hospitals in Bangladesh are encouraging and mirror the findings in other countries.

It was also encouraging to see limited prescribing of repurposed antimicrobials, including antimalarials, antivirals and antiparasitic medicines, given the hype that has surrounded these treatments, particularly hydroxychloroquine, which were without foundation once the findings from robust studies, including the WHO Solidarity and the UK Recovery studies, became known. This is important for promoting evidence-based approaches in the future.

However, high rates of the prescribing of antibiotics, often empiric, even among hospitals stating they are following the Paediatric Association guidelines, coupled with limited switching to oral formulations, are a concern. These issues need to be urgently addressed in Bangladesh, going forward, given the already high rates of AMR in the country coupled with ongoing resource pressures. This is important to reduce future morbidity, mortality, and costs. The instigation of local antibiograms and ASPs are key ways forward to improve future antibiotic use in hospitals in Bangladesh as well as LMICs generally. We will be monitoring such activities in the future. Funding: There was no funding for this paper. The data collection and the development of the paper was funded by the co-authors. Informed Consent Statement: As mentioned, parents or guardians were not approached for consent since this was a retrospective study based on data collated from patients' medical records, with no direct contact with children, their parents, or guardians. This is in line with previous point prevalence studies undertaken by the co-authors [84, 86, [88] [89] [90] 92, 112] . Data Availability Statement: Further data regarding the study is available upon reasonable request.

Routine childhood immunisation during the COVID-19 pandemic in Africa: A benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection

Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries

COVID-19 in children in Bangladesh: Situation analysis

The Impact of the COVID-19 Pandemic on Immunization Campaigns and Programs: A Systematic Review

Implications of COVID-19-induced nationwide lockdown on children's behaviour in Punjab, India. Child Care Health Dev

Routine Vaccination Coverage-Worldwide

Post-disruption catch-up of child immunisation and health-care services in Bangladesh

Coronavirus disease 2019 (COVID-19) in children and/or adolescents: A meta-analysis

COVID-19: A UK Children's Hospital Experience

SARS-CoV-2 (COVID-19): What do we know about children? A systematic review

Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis

Clinical characteristics, treatment and outcomes of paediatric COVID-19: A systematic review and meta-analysis

A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19)

The response to COVID 19 across countries and the implications for future pandemics

COVID-19 infection in children: A systematic review and meta-analysis of clinical features and laboratory findings

Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients

Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Compr

Paradigm Shift in Antimicrobial Resistance Pattern of Bacterial Isolates during the COVID-19 Pandemic

Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis

Antibiotic prescribing in patients with COVID-19: Rapid review and meta-analysis

Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: Experience from a single hospital cluster

Antibiotics 2022

On behalf of the Catalan Infection Control Antimicrobial Stewardship Program. Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic

Antibiotic Prescribing Patterns at COVID-19 Dedicated Wards in Bangladesh: Findings from a

Use of Antimicrobials among Suspected COVID-19 Patients at Selected Hospitals, Bangladesh: Findings from the First Wave of COVID-19 Pandemic

The cost of antimicrobial resistance

Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis

Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis

Potential ways to address antimicrobial resistance across India and wider exacerbated by COVID-19

How COVID-19 is accelerating the threat of antimicrobial resistance

COVID-19 and Antimicrobial Resistance: A Review

Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health

Antibiotic resistance in Bangladesh: A systematic review

Antibiotic Use and Resistance in Bangladesh-Situational Analysis and Recommendations

Antibiotic resistance and sensitivity pattern of Metallo-β-Lactamase Producing Gram-Negative Bacilli in ventilator-associated pneumonia in the intensive care unit of a public medical school hospital in Bangladesh

Potential Strategies to Improve Antimicrobial Utilisation in Hospitals in Bangladesh Building on Experiences Across Developing Countries

Characteristics of Children With Kawasaki Disease-Like Signs in COVID-19 Pandemic: A Systematic Review

COVID-19 and multisystem inflammatory syndrome in children: A systematic review and meta-analysis

COVID-19 in Children: A Review and Parallels to Other Hyperinflammatory Syndromes

WHO. Who Discontinues Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19. Available on

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial

Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19

COVID-19: Remdesivir has little or no impact on survival, WHO trial shows

Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications

Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications

COVID-19: Ivermectin's politicisation is a warning sign for doctors

Misleading clinical evidence and systematic reviews on ivermectin for COVID-19

Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis

Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings

Key findings regarding COVID 19 in Bangladesh and wider and their implications

Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications

Changes in availability, utilization, and prices of medicines and protection equipment for COVID-19 in an Urban population of Northern Nigeria

World Health Organisation. Operational Considerations for Case Management of COVID-19 in Health Facility and Community: Interim Guidance

World Health Organisation

Countering Misinformation about COVID-19

Vaccines and Treatment of COVID-19

Best Practice-Coronavirus Disease 2019 (COVID-19)

COVID-19 PICU guidelines: For high-and limited-resource settings

Government of the People's Republic of Bangladesh. National Guidelines on Clinical Management of Coronavirus Disease

Management Guideline for Paediatric COVID-19

Pilot Study on the Current Management of Children with COVID-19 In Hospitals in Bangladesh; Findings and Implications

Current Management of Children with COVID-19 in Hospitals in India; Pilot Study and Findings

Ministry of Health & Family Welfare Government of India. Guidelines for Management of COVID-19 in Children (Below 18 Years)

Guidelines on the Case Management of COVID-19 in Kenya

Antibiotics Prescribing in Intensive Care Settings during the COVID-19 Era: A Systematic Review

Value of hospital antimicrobial stewardship programs [ASPs]: A systematic review

Ashiru-Oredope, D. Implementation of antimicrobial stewardship programmes in African countries: A systematic literature review

A pharmacist-led prospective antibiotic stewardship intervention improves compliance to communityacquired pneumonia guidelines in 39 public and private hospitals across South Africa

Key Issues Surrounding Appropriate Antibiotic Use for Prevention of Surgical Site Infections in Low-and Middle-Income Countries: A Narrative Review and the Implications

Supporting antimicrobial stewardship in Ghana: Evaluation of the impact of training on knowledge and attitudes of healthcare professionals in two hospitals

Impact of antibiotic stewardship programmes in Asia: A systematic review and meta-analysis

A decision support system for antibiotic prescription based on local cumulative antibiograms

Antimicrobial stewardship and antibiograms: Importance of moving beyond traditional antibiograms

Antimicrobial Stewardship in Bangladesh: A Pharmacist's Perspective

Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): An analysis of paediatric survey data from 56 countries

Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe

What prevents the intravenous to oral antibiotic switch? A qualitative study of hospital doctors' accounts of what influences their clinical practice

Parenteral to Oral Conversion of Fluoroquinolones: Low-Hanging Fruit for Antimicrobial Stewardship Programs?

Beyond IV to PO Switch Therapy: Oral Antimicrobial Therapy. Infectious Disease News

Tackling antimicrobial resistance in Bangladesh: A scoping review of policy and practice in human, animal and environment sectors

Is the effect of COVID-19 on children underestimated in low-and middle-income countries?

Point prevalence study of antimicrobial use among hospitals across Botswana; findings and implications

A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: Findings and implications

Point prevalence surveys of antimicrobial use: A systematic review and the implications

A point prevalence survey of antimicrobial utilisation patterns and quality indices amongst hospitals in South Africa; findings and implications

A multicentre point prevalence study of antibiotics utilization in hospitalised patients in an urban secondary and a tertiary healthcare facilities in Nigeria: Findings and implications

Antibiotic consumption among hospitalized neonates and children in Punjab province

Point prevalence survey of antibiotic use and resistance at a referral hospital in Kenya: Findings and implications

A multicentre point prevalence survey of hospital antibiotic prescribing and quality indices in the Kurdistan regional government of Northern Iraq: The need for urgent action

Antimicrobial point prevalence surveys in two Ghanaian hospitals: Opportunities for antimicrobial stewardship

Antibiotic prescribing patterns at a leading referral hospital in Kenya: A point prevalence survey

Possible role of vitamin D in COVID-19 infection in pediatric population

Smoking and comorbidities are associated with COVID-19 severity and mortality in 565 patients treated in Turkey: A retrospective observational study

Factors associated with COVID-19-related death using OpenSAFELY

Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool

Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: An analysis of sales data from 70 middle-income and high-income countries

Appropriate antibiotic use reduces length of hospital stay

Switch over from intravenous to oral therapy: A concise overview

Dexamethasone in Hospitalized Patients with COVID-19

Role of vitamins and minerals as immunity boosters in COVID-19

Vitamin C in the Treatment of COVID-19

Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: Results of an internet-based global point prevalence survey

Compliance to prescribing guidelines among public health care facilities in Namibia; findings and implications

Compliance to guidelines for the prescribing of antibiotics in acute infections at Namibia's national referral hospital: A pilot study and the implications

Assessment of antimicrobial use and prescribing practices among pediatric inpatients in Zimbabwe

Assessment of adherence to pneumonia guidelines and its determinants in an ambulatory care clinic in Ghana: Findings and implications for the future

Combating antibiotic resistance using guidelines and enhanced stewardship in Kenya: A protocol for an implementation science approach

Why Compliance to National Prescribing Guidelines is Important Especially across Sub-Saharan Africa and Suggestions for the Future

Initiatives and reforms across Scotland in recent years to improve prescribing; findings and global implications of drug prescriptions

Evidence-based public policy making for medicines across countries: Findings and implications for the future

Feasibility of using point prevalence surveys to assess antimicrobial utilisation in public hospitals in South Africa: A pilot study and implications

The authors would like to thank Niam Chy from the University of Chittagong, Bangladesh, for his help with producing the figures.

The authors declare no conflict of interest.